TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus has been on expanding in the US wound care and orthopaedic markets: in August 2017, TRX acquired CellRight Technologies, providing synergistic bone regeneration technology. Full-year 2017 results will be the first to reflect the acquisition and will include five months of the enlarged entity. Sales from all three business segments are forecast to be strong (total £5.15m). We set out our underlying growth expectations below.
If you'd like to be introduced to the team at Tissue Regenix, get in touch.Request a meeting